| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.00001 per share |
| (b) | Name of Issuer:
enVVeno Medical Corp |
| (c) | Address of Issuer's Principal Executive Offices:
70 Doppler, Irvine,
CALIFORNIA
, 92618. |
Item 1 Comment:
Northstrive Fund (as defined below) and Mr. Braeden Lichti previously filed a Schedule 13G on February 10, 2026 (the "Schedule 13G"). This Statement on Schedule 13D relates to the common stock, par value $0.00001 per share (the "Common Stock"), of EnVVeno Medical Corporation (the "Issuer") and amends the Schedule 13G. The principal executive offices of the Issuer are located at 70 Doppler, Irvine, CA 92618. |
| Item 2. | Identity and Background |
|
| (a) | This Schedule 13D is filed jointly by Northstrive Fund II LP ("Northstrive Fund") and Mr. Braeden Lichti (together with Northstrive Fund, the "Reporting Persons").
The shares of Common Stock are held jointly by the Reporting Persons. Mr. Lichti is, as of the date of this Schedule 13D, the Manager of Northstrive Fund, and he has voting and investment power of those shares of Common Stock held by Northstrive Fund. |
| (b) | The address of each of the Reporting Persons is 120 Newport Center Drive, Newport Beach, CA 92660. |
| (c) | Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company. |
| (d) | Neither of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. |
| (e) | None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. |
| (f) | Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada. |
| Item 3. | Source and Amount of Funds or Other Consideration |
| | The information set forth in Item 4 is incorporated by reference herein. Northstrive Fund used working capital as the source of funds for its purchase of the Common Stock. Mr. Lichti used personal funds to purchase his shares of Common Stock. |
| Item 4. | Purpose of Transaction |
| | As of February 10, 2026, the Reporting Persons beneficially owned 33,151 shares of Common Stock, representing 5.05% of the Issuer's issued and outstanding Common Stock. This percentage was calculated based on 655,606 shares of the Issuer's issued and outstanding shares of Common Stock on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the Commission on January 20, 2026.
On February 10, 2026, neither of the Reporting Persons had control or influence intent in the Issuer. This Schedule 13D is being filed to disclose Northstrive's Fund letter to the Board of Directors of the Issuer dated February 20, 2026 (the "Board Letter"). The Board Letter includes, among other things, Northstrive's Fund recommendations to the Board to immediately halt all clinical operations and launch a formal strategic review to either return capital to shareholders or pursue a merger or reverse merger to maximize shareholder value while preserving cash and minimizing further burn and dilution. Northstrive Fund has requested to meet with the senior management of the Issuer in the Board Letter. The Board Letter is filed herein as Exhibit A. As the Board Letter indicates an intent by the Reporting Persons with a purpose or effect to potentially change or influence control of the Issuer, the Reporting Persons have deemed it appropriate to amend the Schedule 13G by filing this Schedule 13D.
The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Common Stock, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate which may include liquidation or further accumulation of shares. In addition, the Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) propose or consider one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D. |
| Item 5. | Interest in Securities of the Issuer |
| (a) | See the information contained on the cover pages of this Schedule 13D, which is incorporated herein by reference. The percentage of Common Stock reported as beneficially owned by each Reporting Person is based on 655,606 shares of the Issuer's issued and outstanding shares of Common Stock on January 20, 2026, as reported on the Issuer's Current Report on Form 8-K filed with the Commission on January 20, 2026. |
| (b) | Sole power to vote or to direct the vote:
Northstrive Fund II LP: 0 shares
Braeden Lichti: 13,022 shares
Shared power to vote or to direct the vote:
Northstrive Fund II LP: 20,129 shares
Braeden Lichti: 20,129 shares
Sole power to dispose or to direct the disposition of:
Northstrive Fund II LP: 0 shares
Braeden Lichti: 13,022 shares
Shared power to dispose or to direct the disposition:
Northstrive Fund II LP: 20,129 shares
Braeden Lichti: 20,129 shares |
| (c) | The information set forth in Item 3 above is incorporated herein by reference. |
| (d) | Not applicable. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
| | The information in Items 3 and 4 is incorporated herein by reference. |
| Item 7. | Material to be Filed as Exhibits. |
| | Exhibit A Letter to the Board of Directors of Issuer
Exhibit B Transactions completed by Reporting Persons in the Common Stock |
